RE: With £99.6m cash27 Jul 2022 08:36
It's definitely a combination of poor operational performance and the wider market uncertainty. In 'normal' times it would be extremely hard to find companies that are valued below their NAV besides special circumstances (almost always biotechs) but now I could name four or five straight off and there are plenty more than that.
The market, especially small cap Aim stocks, has become incredibly short term thinking. For now it's not looking any further than it's nose and if there's no positive catalysts immediately ahead, if there's any chance that the next bit of news good be negative think another poor trading update in a few month's time for example), then the share price falls further or stays deflated no matter the valuation.
In reality, despite the failure to kick on this year and prove that novacyt are ready to thrive post-covid (whilst still generating revs from covid), there is still enormous value here. We know this is a sector that is growing, we know medicine and testing is becoming ever more personalised and moving into the home, something ncyt are well prepared to take advantage of, we still have those links with the world's biggest NGOs etc Even if DA fails to turn it around we should still have tens of millions for a new CEO to come in and turn it around.
Obviously we are not down here at 105p because of the market alone and imo the bigger reason is the failure of management however all the time the cash in the bank remains high there is months and years to turn this ship around. All is not lost yet but it's sure been a painful journey up until now!